1) Findings: Insights and developments globally on the subject of cancer.
2) Companies: Updates and progress reports on Consortium member companies.
3) Industry: Important developments from throughout the field of cancer.
The Trial TMIST is a randomized breast screening trial that will help researchers learn about the best ways to find breast cancer in women who have no symptoms. It compares two types of Food and Drug Administration (FDA)-approved digital […]
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, according to preliminary results from a clinical trial. About 2% of patients with non-small cell lung cancer (NSCLC) […]
Men may be more likely than women to die after being diagnosed with breast cancer, particularly during the first 5 years after diagnosis, a new study suggests. In the study, the 5-year overall […]
“The essence of precision medicine, in particular precision oncology, is to make cancer management more precise based on genomic mapping and molecular characterization of the unique tumors for each patient,” says Dr. […]
Cellanyx, a Massachusetts-based diagnostic company, has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. Their unique approach provides quantitative and actionable information […]
For African American men, the risk of dying from low-grade prostate cancer is double that of men of other races, a new study has found. But, despite the difference, the risk is still small. […]
The investigational drug darolutamide can help delay the spread of prostate cancer to other parts of the body in men with nonmetastatic castration-resistant disease, according to results from a large clinical trial. In addition, the drug appears […]
The treatment landscape for metastatic prostate cancer is shifting and expanding yet again, according to new findings from two large clinical trials presented at the 2019 annual meeting of the American Society […]
